Venetoclax CACAG versus 3+7 regimen acute monocytic leukemia

ClinicalTrials.gov has added a new clinical trial registration (NCT07512700) for a Phase 2 study comparing venetoclax combined with CAG (CACAG regimen) against the traditional 3+7 regimen (cytarabine plus daunorubicin) for acute monocytic leukemia, a subtype of acute myeloid leukemia. The trial targets adult patients and is listed as actively recruiting.

Clinical investigators and sponsors should ensure their trial participation aligns with institutional review board requirements and FDA regulations. Pharmaceutical companies conducting oncology trials should verify their studies are properly registered. Patients and healthcare providers seeking trial enrollment should consult ClinicalTrials.gov for eligibility criteria and contact information.